SHARE NOW
As we enter the 7-week countdown to Advanced Therapies Europe, the Phacilitate team has been considering their top highlights from the agenda and networking event schedule, and how we plan to bring that well-known ‘Phacilitate magic’ to our new, Portugal location.
Advanced therapies continue to demonstrate groundbreaking innovations with transformative potential for the future of healthcare,–and the expansion of capabilities within the biopharmaceutical industry.
While the future is certainly bright for the field, there remain challenges and obstacles to progress that need to be addressed. While some of these challenges are by no means geographically specific, it cannot be denied that different markets and regions do have their own, unique challenges, and those operating within these areas are in need of a forum for exploring solutions to these challenges, and opportunity for a collaborative, strategic approach.
Europe, for example, has seen immense opportunity over recent years, but routes to market access and various legislative or regulatory barriers – amongst others – have been cited as obstacles to address and overcome in order to get ATMPs over the line. There are conversations that need to had, concepts and solutions that need to be presented and collaborations required to facilitate progression for ATMPs within the European landscape.
Enter, Phacilitate’s Advanced Therapies Europe…
Advanced Therapies Europe is Phacilitate’s second annual meeting that focuses on addressing challenges specific to the European market. The event is this year moving to Portugal, taking place from 5th–7th September 2023, where esteemed professionals, thought leaders, and visionaries will gather to share insights, provide networking opportunities, and kick-start hot topic conversations the industry needs to strive in this newly competitive, complex and compelling space, shaping the landscape of advanced therapies in Europe and beyond.
Don’t Miss:
5th September: Women in Advanced Therapies Meeting & Summer Poolside BBQ
The event will kick off with an empowering Women in Advanced Therapies meeting (WIAT) with an opening panel, engaging roundtable discussions and invaluable networking sessions. This day is dedicated to celebrating the contribution of women in this fast-evolving field.
Becky Johnson-Kent, Director of Commercial Partnerships and Head of Women in Advanced Therapies shares that:
“The inclusion of a Women in Advanced Therapies (WIAT) pre-day alongside Advanced Therapies Europe is vital to showcase the power of collaboration, amplifying voices and fostering a diverse community of leaders. Europe is an evolving space within advanced therapies, and it is critical that support for women in this space starts early and continues throughout every career pathway. In an environment where change happens often and at pace, a diverse support network is a key component to feeling valued and included, nurturing free thinking and thought leadership. By developing the women within advanced therapies, we in turn develop the sector.
The day will conclude with a delightful Summer Poolside BBQ in the spirit of building meaningful connections. A chance for attendees to relax, exchange ideas and most importantly develop bonds in a laid-back setting, setting the stage for the sessions to follow.
How are you enjoying this blog post? Let us know your thoughts, here >>
6th September: Setting the Agenda for Advanced Therapies
As the main event unfolds from 6th September, the opening panel focusses on the European cell and gene therapy landscape
Carefully selected speakers will explore the theme, ‘Thriving or Surviving – An Analysis of the Advanced Therapies Landscape Within Europe and What the Future Holds’, offering a glimpse into the infinite possibilities that lie ahead. Speakers include:
- Anthony Davies, Founder & Chief Executive Officer, Dark Horse Consulting Group
- Ben Doak, Head of Innovative Treatments, NHS England
- Elisabetta Zanon, Director of EU Public Affairs & Advocacy, Alliance for Regenerative Medicine
- Helen Tayton-Martin, Chief Business & Strategy Officer, AdaptImmune
- Almira Barolome, Executive Director, Commercial Development, Advanced Therapies, FUJIFILM DioSynth
- Miguel Forte, President Elect, ISCT
This session is followed by our first-ever structured debate, ‘The Cost On A Cure – Do the Results Justify the Price?’ a proposition vs. opposition, Oxford rules, with input from:
- Katrien Reynders, HollandBio
- Christian Chabbannon, EBMT/GoCART
- Lucy Ellerker Jones, Opie Foundation
- Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs
- Joshi Venugopal, General Manager and Head of Europe, Novartis
Outside of the opening sessions, a myriad of hot topics and challenges are represented across the two-day agenda, compiled in response to feedback from the industry and esteemed Phacilitate Advisory Board.
Digitalization
Digitalization plays a big part in the 2023 agenda, with multiple sessions and workshops touching on how disruptive developments in digitalization, AI and virtualization are supporting ATMP progress, how orchestration is revolutionizing supply and value chains and getting therapies to patients faster.
Patient and Clinical Considerations
Patient and clinical considerations for cell and gene therapy are more critically important than ever, and we’ll be exploring how to reach more patients and how to engage with healthcare organizations, governments, and how to do better for patients throughout the entire drug lifecycle
Distinct Modalities
A focused session on distinct modalities explores breakthrough companies in autologous and allogeneic cell therapies as well as gene therapies, with updates from Janssen, Cellectis, Remedium bio, AdaptImmune and many more.
Manufacturing, Automation and Supply Chain Revolution
Deep dives into manufacturing, automation and supply chain revolution across the two main agenda days will feature insights from leading experts from, but not limited to Takeda, Orchard Therapeutics, AstraZeneca and CSL Behring, along with many more.
Regulatory and Market Access
Panel discussions will be hosted around regulatory and market access considerations for European and global markets. Engage in dynamic panel discussions that shed light on the regulatory and market access challenges and opportunities facing advanced therapies in both European and global markets, and gain a deeper understanding of the regulatory landscape and its impact on future breakthroughs.
Exhibition Networking Drinks
As the event draws to a close, the Exhibition Networking Drinks offers a final chance for attendees to continue important conversions while winding down and processing impactful insights gained from just a few days of Advanced Therapies Europe. Together, we aim to unlock the potential of these life-changing treatments and to contribute to the creation of a world – or at least a region – where cutting-edge medicine knows no bounds.
As Kim Barnes, Executive Vice President for Phacilitate comments:
“I cannot wait for Advanced Therapies Europe this year. With the event being hosted in Portugal, I am especially excited to be able to bring some of the ‘Phacilitate magic’ to the event that we have become so famous for. At Phacilitate, we’re dedicated to advancing the next pillar of medicine and believe the key to this is through collaboration and meaningful connections. Bringing thought leaders together while creating an engaging environment to execute valuable discussions is our bread and butter, and serves as an amazing opportunity to support the industry with continual progression.”
Will you be joining us in Lisbon? If you’re yet to register your place, make sure you do so by 28th July to benefit from the Early Bird discounts!
We look forward to seeing you there.
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
